Compare AbCellera Biologics Inc (ABCL) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Colgate-Palmolive Company — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Colgate-Palmolive Company trades at $93.3 (market cap $76.04B). The key difference: Colgate-Palmolive Company is far larger — about 32.4× AbCellera Biologics Inc's market cap, and Colgate-Palmolive Company pays a 2.23% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CL | |
|---|---|---|
Market Cap | $2.35B | $76.04B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $99.14 |
52-Week Low | $2.78 | $74.98 |
Enterprise Value | $1.99B | $82.68B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Colgate-Palmolive (CL) trades at $95.03, down 0.11% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company maintains strong profitability with a 60.06% gross margin and 10.04% net margin, though its P/E of 36.2 and P/B of 515.38 reflect premium valuation. Positive sentiment is driven by dividend consistency and strategic growth initiatives, while cash flow trends show stable operational performance.
Outlook remains cautiously optimistic with analyst consensus at Buy 42%, Hold 53%, and a $95.50 price target. Key opportunities include international growth and pricing power, but risks involve North American softness and high valuation multiples. The stock's 17% YTD gain underscores resilience, though inflation and competitive pressures warrant monitoring for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
